Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot
CPT®
87527

CPT® Code 87527

Official Description

Infectious agent detection by nucleic acid (DNA or RNA); hepatitis G, quantification

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 87527 refers to a laboratory test designed for the detection of the hepatitis G virus (HGV), also known as GB virus-C (GBV-C), through the analysis of nucleic acids, specifically DNA or RNA. This test is crucial for identifying the presence of the infectious agent in a blood sample. Hepatitis G infection is typically asymptomatic, meaning that individuals may not exhibit noticeable symptoms, and it rarely leads to hepatic inflammation. However, it is often found in conjunction with other viral infections that can cause acute or chronic hepatitis, making its detection important in the context of co-infections. The transmission of HGV occurs primarily through infected blood and blood products, from mother to infant during childbirth, and through sexual contact between partners. The testing process involves a direct probe test, which identifies a unique nucleic acid sequence known as the target sequence of the hepatitis G virus, if it exists in the blood sample. This probe is labeled with either fluorescent or chemiluminescent markers to facilitate detection. The sample undergoes treatment to release nucleic acids from the target organism, allowing the labeled probe to specifically bind to the matching target sequence, forming a stable hybrid. Ribosomal RNA is often the focus of these tests due to its abundance in microorganisms, as it is typically present in thousands of copies compared to the limited copies of genomic DNA. To enhance the sensitivity of the assay, an amplified probe technique is employed, which involves exponentially multiplying the target sequence of hepatitis G virus DNA or RNA into millions of copies. The polymerase chain reaction (PCR) or reverse transcriptase polymerase chain reaction (RT-PCR) is the most commonly utilized amplification method. Following amplification, the replicated sequences are identified using labeled DNA probes. The nucleic acid detection process, particularly with quantification, provides valuable information regarding the number of microorganisms present in the sample. Quantitative or real-time PCR is frequently used to amplify the isolated nucleic acid segment and generate detailed reports that document the absolute or relative amounts of the known nucleic acid sequence, thereby offering insights into the viral load present in the patient’s sample.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The CPT® Code 87527 is indicated for the detection and quantification of the hepatitis G virus (HGV) in patients who may be at risk for co-infections with other hepatitis viruses. The following conditions and scenarios warrant the use of this test:

  • Asymptomatic Individuals Individuals who are asymptomatic but may have been exposed to HGV through blood transfusions, sharing of needles, or other high-risk behaviors.
  • Co-infection Assessment Patients diagnosed with other forms of hepatitis, such as hepatitis B or C, where the presence of HGV may complicate the clinical picture.
  • Monitoring Viral Load Patients undergoing treatment for hepatitis or related conditions, where quantification of HGV can provide insights into the viral load and treatment efficacy.
  • Pregnant Women Pregnant women who may have been exposed to HGV, as the virus can be transmitted from mother to infant during childbirth.

2. Procedure

The procedure for CPT® Code 87527 involves several critical steps to ensure accurate detection and quantification of the hepatitis G virus. The following procedural steps are outlined:

  • Sample Collection A blood sample is collected from the patient, which serves as the source for nucleic acid extraction. Proper collection techniques are essential to avoid contamination and ensure the integrity of the sample.
  • Nucleic Acid Extraction The collected blood sample undergoes treatment to release nucleic acids from any present hepatitis G virus. This step is crucial as it prepares the sample for the subsequent detection process.
  • Probe Hybridization A labeled probe, which is specific to the target sequence of the hepatitis G virus, is introduced to the sample. The probe binds to the target nucleic acid sequence if it is present, forming a stable hybrid. This step is essential for the identification of the virus.
  • Amplification of Target Sequence To enhance the sensitivity of the test, the target sequence of the hepatitis G virus DNA or RNA is amplified using techniques such as polymerase chain reaction (PCR) or reverse transcriptase polymerase chain reaction (RT-PCR). This amplification process increases the number of copies of the target sequence, making it easier to detect.
  • Detection and Quantification After amplification, the replicated sequences are identified using labeled DNA probes. The quantification of the amplified nucleic acid segments is performed, often utilizing quantitative or real-time PCR methods. This step provides a measurement of the viral load present in the sample, which is critical for assessing the extent of infection.

3. Post-Procedure

After the completion of the procedure associated with CPT® Code 87527, the laboratory will analyze the results and generate a report detailing the presence and quantity of the hepatitis G virus in the sample. The results are typically communicated to the healthcare provider, who will interpret the findings in the context of the patient's overall clinical picture. Depending on the results, further clinical management may be necessary, including additional testing or treatment options. It is important for healthcare providers to discuss the implications of the test results with the patient, especially in cases where co-infections are present or where the viral load indicates a need for intervention. Follow-up care may also be required to monitor the patient's health and response to any treatments initiated based on the test findings.
Short Descr HEPATITIS G DNA QUANT
Medium Descr IADNA HEPATITIS G QUANTIFICATION
Long Descr Infectious agent detection by nucleic acid (DNA or RNA); hepatitis G, quantification
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 206 - Microscopic examination (bacterial smear, culture, toxicology)
Date
Action
Notes
2011-01-01 Changed Short description changed.
1998-01-01 Added First appearance in code book in 1998.
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"